Stockreport

Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update

Pharvaris N.V. - Ordinary Shares  (PHVS) 
PDF Topline data for RAPIDe-3, a pivotal Phase 3 study of deucrictibant immediate-release capsule for the on-demand treatment of HAE attacks, expected in 4Q2025Enrollment in [Read more]